CoChat
Sign Up
Cited by 250Cancer Research and TreatmentsHepatocellular Carcinoma Treatment and PrognosisAmino Acid Enzymes and Metabolism

Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies

Izzo, Francesco, Marra, Paolo, Beneduce, Gerardo, Castello, Giuseppe, Vallone, Paolo, De Rosa, Vincenzo, Cremona, Franco, Ensor, C. Mark +5 more·2004·Journal of Clinical Oncology
DOI 10.1200/jco.2004.11.120
Open this paper in CoChat — free account

Abstract

Purpose: Recently, we reported that a large number of human hepatocellular cancer (HCC) cell lines were auxotrophic for arginine. Here we report the results obtained with the amino acid–degrading enzyme arginine deiminase (ADI) conjugated to polyethylene glycol (ADI-SS PEG 20,000 mw) as a means of lowering plasma arginine to treat HCC. The study was a cohort dose-escalation phase I/II study. Patients and Methods: Pharmacodynamic studies indicated an ADI-SS PEG 20,000 mw dose level of 160 U/m 2 was sufficient to lower plasma arginine from a resting level of approximately 130 μmol/L to below the level of detection (< 2 μmol/L) for more than 7 days, a dose later defined as the optimal biologic dose. All patients were to receive three cycles at the optimum biologic dose. Results: This therapy was well tolerated, even in patients who had no detectable plasma arginine for 3 continuous months of therapy. Of the 19 patients enrolled, two had a complete response, seven had a partial response, seven had stable disease, and three had progressive disease. The median survival for the 19 patients enrolled on this study was 410 days, with four patients still alive at present (> 680 days). Conclusion: Elimination of all detectable plasma arginine in patients with HCC was well tolerated and seemed to be effective in the treatment of some patients with HCC. Further testing of ADI-SS PEG 20,000 mw in a larger population of individuals with HCC as well as other human tumors auxotrophic for arginine is warranted.

Integrity signals

Registry

Crossref · 10.1200/jco.2004.11.120

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Recombinant pegylated arginine deiminase (ADI-PEG20) has been tested in clinical trials for melanoma and hepatocellular carcinoma with some therapeutic benefit.

    “Recombinant pegylated arginine deiminase (ADI-PEG20) has been tested in clinical trials to treat melanoma and hepatocellular carcinoma with some therapeutic benefit (Ascierto et al., 2005; Izzo et al., 2004; Ott et al., 2013; Szlosarek et al., 2013; Yang et al., 2010).”

    From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Izzo et al., 2004

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., Ng, C., & Curley, S. A.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • From the Pascale National Cancer Institute, Naples, Italy; Phoenix Pharmacologics Inc, and University of Kentucky, Lexington, KY; and M.D. Anderson Cancer Center, University of Texas, Houston, TX.
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2004-05-15
Volume
22
Issue
10
Pages
1815-1822
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2004.11.120
OpenAlex
W2168974457
Cited by
250
References
42
Citations by year
2026: 5 · 2025: 6 · 2024: 7 · 2023: 11 · 2022: 9 · 2021: 14 · 2020: 10 · 2019: 7 · 2018: 16 · 2017: 16 · 2016: 15 · 2015: 13 · 2014: 14 · 2013: 15 · 2012: 15
FWCI
7.32
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biotechnology › Cancer Research and Treatments
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
Keywords
arginine deiminase, pegylated arginine deiminase, hepatocellular carcinoma, arginine auxotrophy, dose escalation, pharmacodynamics, tumor response, survival
MeSH terms
Adult, Aged, Drug Administration Schedule, Female, Carcinoma, Hepatocellular, Humans, Hydrolases, Injections, Intramuscular, Liver Neoplasms, Male, Middle Aged, Polyethylene Glycols, Tomography, X-Ray Computed, Cohort Studies, Survival Analysis, Treatment Outcome, Disease-Free Survival

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review